2-Aminopurine

2-Aminopurine

SCHEMBL383841

Nc1ncc2nc[nH]c2n1.O=[PH](O)O

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
RXFP1 Q9HBX9 1/20 0.40
DPP4 P27487 1/20 0.32
KDM4E B2RXH2 2/20 0.32
MAPT P10636 1/20 0.32
APEX1 P27695 1/20 0.32
RECQL P46063 1/20 0.32
BLM P54132 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
GDA Q9Y2T3 2/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
PARP1 P09874 1/20 0.30
PDPK1 O15530 1/20 0.30
GLA P06280 1/20 0.30
GAA P10253 1/20 0.30
HPGD P15428 1/20 0.30
HSD17B10 Q99714 1/20 0.30
PRKCI P41743 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Aminopurine SCHEMBL5631 0.89 ALDH1A1 (0.48) ALDH1A1RXFP1DPP4KDM4EMAPT
2-Aminopurine SCHEMBL29901502 0.89 ALDH1A1 (0.48) ALDH1A1RXFP1DPP4KDM4EMAPT
2-Aminopurine SCHEMBL28283405 0.87 ALDH1A1 (0.47) ALDH1A1RXFP1DPP4KDM4EMAPT
2-Aminopurine SCHEMBL20305128 0.86 ALDH1A1 (0.41) ALDH1A1RXFP1DPP4KDM4EMAPT
2-Aminopurine SCHEMBL8343847 0.86 ALDH1A1 (0.41) ALDH1A1RXFP1DPP4KDM4EMAPT
2-Aminopurine SCHEMBL1528157 0.84 ALDH1A1 (0.42) ALDH1A1RXFP1KDM4EMAPTAPEX1
2-Aminopurine SCHEMBL5667807 0.83 RXFP1 (0.59) ALDH1A1RXFP1DPP4KDM4EMAPT
2-Aminopurine SCHEMBL4342851 0.83 ALDH1A1 (0.41) ALDH1A1RXFP1KDM4EMAPTAPEX1
2-Aminopurine SCHEMBL10551243 0.81 ALDH1A1 (0.42) ALDH1A1RXFP1KDM4EMAPTAPEX1
2-Aminopurine SCHEMBL9014624 0.79 ALDH1A1 (0.41) ALDH1A1RXFP1KDM4EMAPTAPEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318700-B2 Lung-targeted drugs THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-11-27 US disclosed
US-20120122818-A1 LUNG-TARGETED DRUGS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-05-17 US disclosed
US-8101745-B2 Conjugate cidofovir, idoxuridine, vidarabine, trifluridine, acyclovir, famciclovir penciclovir, valacyclovir, ganciclovir, antiviral, antimicrobial, cancer drug of interest to glycerol ethers or glycerol phosphate ethers THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-01-24 US disclosed
US-20080221061-A1 Lung-Targeted Drugs THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-09-11 US disclosed
US-5877166-A HERPES VIRUS SRI INTERNATIONAL (US) 1999-03-02 US disclosed
WO-1997041133-A1 ENANTIOMERICALLY PURE 2-AMINOPURINE PHOSPHONATE NUCLEOTIDE ANALOGS AS ANTIVIRAL AGENTS SRI INTERNATIONAL (US) 1997-11-06 WO disclosed
WO-1997041133-A1 ENANTIOMERICALLY PURE 2-AMINOPURINE PHOSPHONATE NUCLEOTIDE ANALOGS AS ANTIVIRAL AGENTS SRI INTERNATIONAL (US) 1997-11-06 WO disclosed
WO-1997041133-A1 ENANTIOMERICALLY PURE 2-AMINOPURINE PHOSPHONATE NUCLEOTIDE ANALOGS AS ANTIVIRAL AGENTS SRI INTERNATIONAL (US) 1997-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221061-A1 Lung-Targeted Drugs DGKG, GK, PHOSPHO1 ALDH1A1 4007/4885RXFP1 3459/4885DPP4 2495/4885
US-20120122818-A1 LUNG-TARGETED DRUGS DGKG, GK, PHOSPHO1 ALDH1A1 4007/4885RXFP1 3459/4885DPP4 2495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.